TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7757891

Group type: EXPERIMENTAL
Intervention: Volunteer telephone support program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual services from professionals
Number of subjects: 200
Study: 30654196

Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29547079

Group type: EXPERIMENTAL
Intervention: Polyvictimization with EF scores 1.62 or more standard deviations below the mean
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Polyvictimization with EF scores at the mean or above
Number of subjects: 84
Study: 26846438

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen during an eight-week exercise training program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Medical air during an eight-week exercise training program (sham intervention)
Number of subjects: 110
Study: 25282284

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 7155
Study: 23257428

Group type: COMPARATOR
Intervention: MPO (G-463A) genotype
Number of subjects: 150

Group type: COMPARATOR
Intervention: NQO1 (C-609T) genotype
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined gene analysis of MPO and NQO1 wild genotypes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MPO (G-463A) mutant gene (GA/AA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: NQO1 (C-609T) mutant gene (TC/TT)
Number of subjects: 150
Study: 19146666

Group type: EXPERIMENTAL
Intervention: Positioning pillow
Number of subjects: 124

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Positioning pillow (children over 6 years)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No intervention (control, children over 6 years)
Number of subjects: 124
Study: 16947053

Group type: EXPERIMENTAL
Intervention: Tenodesis without tenotomy (group 1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tenodesis with tenotomy (group 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 22
Study: 15507172

Group type: EXPERIMENTAL
Intervention: Capecitabine/docetaxel combination therapy
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Poststudy single-agent capecitabine
Number of subjects: 511

Group type: COMPARATOR
Intervention: Poststudy vinorelbine-containing chemotherapy
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Discontinuing docetaxel and continuing capecitabine
Number of subjects: 511
Study: 11838756

Group type: EXPERIMENTAL
Intervention: Elective cervical cerclage (n=27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Serial weekly evaluations of the cervix by transvaginal ultrasonograms (n=28)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 55
Study: 9552024

Group type: EXPERIMENTAL
Intervention: Observation without therapeutic intervention
Number of subjects: 12
Study: 7914118

Group type: EXPERIMENTAL
Intervention: Proxodolol 10 mg tablets
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Proxodolol 40 mg tablets
Number of subjects: 29
Study: 3072783

Group type: EXPERIMENTAL
Intervention: nifedipine (20 mg p.o.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BAY 1 8201 (100 mg p.o.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 31672505

Group type: EXPERIMENTAL
Intervention: Ceramic-on-Ceramic Total Hip Arthroplasty (C-O-C THA)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Ceramic-on-Highly Cross-Linked Polyethylene Total Hip Arthroplasty (C-O-HXLPE THA)
Number of subjects: 133
Study: 30156058

Group type: EXPERIMENTAL
Intervention: Enhanced program (NFN+)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard home visitation program (NFN)
Number of subjects: 57
Study: 28782123

Group type: EXPERIMENTAL
Intervention: Fresh blood (nonleukoreduced RBCs stored for not more than 14 days)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Old blood (nonleukoreduced RBCs stored for more than 14 days)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Old blood
Number of subjects: 199

Group type: COMPARATOR
Intervention: Old blood (as-treated analysis)
Number of subjects: 199
Study: 24845604

Group type: COMPARATOR
Intervention: Resistance band training
Number of subjects: 7
Study: 23490092

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment group, n=35
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group, n=32
Number of subjects: 67
Study: 21192310

Group type: EXPERIMENTAL
Intervention: PPI therapy (pantoprazole and omeprazole)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: PPI therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard dosing of mycophenolate mofetil (1.0 g twice daily)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Intensified dosing of mycophenolate mofetil (1.5 g twice daily on Days 1‐5, then 1.0 g twice daily)
Number of subjects: 126
Study: 18461104

Group type: EXPERIMENTAL
Intervention: Low-intensity walking program (W)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional management alone (C)
Number of subjects: 30
Study: 16603730

Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 microg bid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14663457

Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg) with oral morphine (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with oral morphine (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg) with intravenous morphine (0.15 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with intravenous morphine (0.15 mg/kg)
Number of subjects: 0
Study: 10997950

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (7.7 g/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8865958

Group type: EXPERIMENTAL
Intervention: Carbohydrate-deficient transferrin (CDT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Serum gamma-glutamyltransferase (GGT)
Number of subjects: 35
Study: 1739574

Group type: EXPERIMENTAL
Intervention: Isoflurane (slow washout)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Enflurane (slow washout)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Isoflurane (fast washout)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Enflurane (fast washout)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Halothane (slow washout)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Halothane (fast washout)
Number of subjects: 46
Study: 6691715

Group type: EXPERIMENTAL
Intervention: PUVA (oral methoxsalen plus longwave UV light)
Number of subjects: 183

Group type: COMPARATOR
Intervention: UV-B therapy
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: UV-B phototherapy
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Extra UV-B treatment to leg lesions
Number of subjects: 183
Study: 29649827

Group type: EXPERIMENTAL
Intervention: Safe driving skill program consisting of 10 1-hour classroom sessions and 10 1-hour on-road sessions
Number of subjects: 160

Group type: COMPARATOR
Intervention: 1 classroom education (Control)
Number of subjects: 160
Study: 29498550

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI; 412 hr, $4,373 per participant)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI)
Number of subjects: 325
Study: 27141894

Group type: EXPERIMENTAL
Intervention: Noninvasive T2DM prediction model (model 4)
Number of subjects: 12285

Group type: COMPARATOR
Intervention: FINDRISC model
Number of subjects: 12285
Study: 24705203

Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 0
Study: 22364419

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Imatinib 300 mg daily
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg daily
Number of subjects: 481
Study: 20738472

Group type: EXPERIMENTAL
Intervention: Treatment (specific treatment not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19127033

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPI), specifically Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPI), specifically Tirofiban
Number of subjects: 0
Study: 15369998

Group type: EXPERIMENTAL
Intervention: Maori participants
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Non-Maori participants
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Overall participants (Maori and non-Maori)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Categorical ethnicity distinction (Maori and non-Maori)
Number of subjects: 205
Study: 11600526

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (50 mg/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9539984

Group type: EXPERIMENTAL
Intervention: Intensive therapy (IT) for IDDM
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (refusers)
Number of subjects: 99
Study: 8026248

Group type: EXPERIMENTAL
Intervention: Cisapride (30-60 mg/day for 12.6 ± 2.6 months)
Number of subjects: 11
Study: 2910633

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 141904

Group type: EXPERIMENTAL
Intervention: Routine postoperative physiotherapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Meniscectomy patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy volunteer controls
Number of subjects: 16
Study: 31944371

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Adolescents (DBT-A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Treatment as usual plus group sessions (TAU + GS)
Number of subjects: 35
Study: 30346097

Group type: EXPERIMENTAL
Intervention: Increased temperature (average of 1.4°C over a growing season) and additional rainwater (10% of the monthly mean added weekly, 40% total)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 24
Study: 27727268

Group type: EXPERIMENTAL
Intervention: Topical aerosol containing chlorfenvinphos 4.8%, dichlorphos 0.75% and gentian violet 0.145%
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study: 25153952

Group type: EXPERIMENTAL
Intervention: Positive mood induced by showing comedy movie clips to 100 participants
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Negative mood induced by showing tragedy movie clips to another 100 participants
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both mood states were assessed in decision making under uncertainty
Number of subjects: 200
Study: 22577354

Group type: EXPERIMENTAL
Intervention: Combination of glucosamine sulfate and NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucosamine sulfate
Number of subjects: 0
Study: 21116009

Group type: EXPERIMENTAL
Intervention: Near-continuous live HVPC for 72 h postinjury
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo HVPC for 72 h postinjury
Number of subjects: 50
Study: 18937609

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day plus micronised fenofibrate 200 mg/day
Number of subjects: 30
Study: 15953425

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone (4 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retrobulbar injections of triamcinolone (40 mg, three times)
Number of subjects: 60
Study: 14654745

Group type: EXPERIMENTAL
Intervention: S‐CBP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P‐CBP
Number of subjects: 30

Group type: COMPARATOR
Intervention: S‐HBP
Number of subjects: 30
Study: 10942856

Group type: EXPERIMENTAL
Intervention: 2 mg sublingual buprenorphine (BUP)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 16 mg sublingual buprenorphine (BUP)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0 mg buprenorphine (detoxification)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 3
Study: 8774028

Group type: EXPERIMENTAL
Intervention: Caffeine (exact dosage not specified)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (normal practice)
Number of subjects: 93
Study: 1352868

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid derivative (bis-hemisuccinate bisodic salt) at a dose of 600 mg/day for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study: 6376317

Group type: EXPERIMENTAL
Intervention: Large mediastinal masses (MT ratio >= 0.35)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Moderate mediastinal invasion (MT ratio < 0.35)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: No mediastinal involvement
Number of subjects: 154

Group type: COMPARATOR
Intervention: Combined modality therapy utilizing MOPP chemotherapy
Number of subjects: 154
Study: 31080129

Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WB-MRI)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Standard pathways
Number of subjects: 353
Study: 30026333

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.05 mg
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.3 mg
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.3 mg
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study: 26824731

Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA) supplements
Number of subjects: 18775

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN) supplements
Number of subjects: 18775

Group type: COMPARATOR
Intervention: Folic acid (FA) supplements
Number of subjects: 18775
Study: 25946854

Group type: EXPERIMENTAL
Intervention: 5% solution of ascorbic acid, 20 ml/day for 20 days
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cytoflavin, 20 ml (10.0 ml/drip 2 times a day) for 10 days
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cytoflavin, extended to 20 days with a dose of 10 ml/day from 11th to 20th day
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cytoflavin for 20 days in patients with 18-20 points on NIH scale
Number of subjects: 185
Study: 22500384

Group type: EXPERIMENTAL
Intervention: Lamivudine + Fuzheng Huayu Capsule (FHC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lamivudine alone (Control)
Number of subjects: 80
Study: 20569451

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 7492

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 7492

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 7492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7492

Group type: EXPERIMENTAL
Intervention: Bazedoxifene or Raloxifene
Number of subjects: 7492

Group type: EXPERIMENTAL
Intervention: Active treatment groups (Bazedoxifene and Raloxifene)
Number of subjects: 7492

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg and 40 mg
Number of subjects: 7492

Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 7492

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7492

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 7492
Study: 17943542

Group type: EXPERIMENTAL
Intervention: dydrogesterone 20 mg/day
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: dydrogesterone 30 mg/day
Number of subjects: 1173
Study: 15925752

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 6083
Study: 12036194

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 17
Study: 10101626

Group type: EXPERIMENTAL
Intervention: 2 mg of morphine (PCA)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 20 mg of tramadol (PCA)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (PCA)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Morphine (escape medication for non-responders)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Loading dose
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Loading dose and pain scores during the first 30 min
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Overall response to post-operative pain management
Number of subjects: 161
Study: 7593695

Group type: EXPERIMENTAL
Intervention: 3 different types of manual toothbrush
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Planimetric plaque area method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clinical or nonclinical personnel analysis
Number of subjects: 30
Study: 3314516

Group type: EXPERIMENTAL
Intervention: 5% dextrose (50 gm of glucose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 32
Study: 28893574

Group type: EXPERIMENTAL
Intervention: Real stimulation over left DLPFC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation over left DLPFC
Number of subjects: 20
Study: 26386702

Group type: EXPERIMENTAL
Intervention: HES outpatient dataset
Number of subjects: 370
Study: 25632745

Group type: EXPERIMENTAL
Intervention: Tongfu Jinghua Decoction (TJD) combined with conventional Western medical treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Western medical treatment alone
Number of subjects: 60
Study: 23349296

Group type: EXPERIMENTAL
Intervention: Na/K citrate
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study: 18523036

Group type: EXPERIMENTAL
Intervention: Difflam throat spray
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo throat spray
Number of subjects: 45
Study: 18640466

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1b 250 microg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1b 500 microg
Number of subjects: 71

Group type: COMPARATOR
Intervention: MRI evaluation
Number of subjects: 71
Study: 20961349

Group type: EXPERIMENTAL
Intervention: Long-pulse Nd:YAG laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combination Q-switched Nd:YAG laser with topical carbon lotion followed by long-pulse Nd:YAG
Number of subjects: 20
Study: 15705723

Group type: EXPERIMENTAL
Intervention: Targeting a specific sound pressure level
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Speaking twice as loud as comfortable
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Speaking in noise
Number of subjects: 30
Study: 11558980

Group type: EXPERIMENTAL
Intervention: Pain Education Programme (PEP)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 313
Study: 9141936

Group type: EXPERIMENTAL
Intervention: Preemptive ketamine (0.5 mg/kg followed by infusion of 10 micrograms.kg‐1.min‐1 until abdominal closure)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Postwound closure ketamine (0.5 mg/kg immediately after abdominal closure)
Number of subjects: 40
Study: 8494755

Group type: EXPERIMENTAL
Intervention: Health education package (pamphlets, workbooks, video)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Wearing sunscreen
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Covering up in the sun
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Sitting in the shade
Number of subjects: 543
Study: 3556308

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (0.5 mg PGE2 in 2.5 ml Triacetin gel, Prepidil, intracervically)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin induction without pretreatment (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cervical priming with PGE2
Number of subjects: 100

Group type: COMPARATOR
Intervention: No cervical priming (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PGE2 gel group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin group (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PGE2 treatment
Number of subjects: 100
Study: 11478762

Group type: EXPERIMENTAL
Intervention: Micronutrient appetite normaliser formulation (neogadine) administered for up to 30 days
Number of subjects: 722
Study: 30884155

Group type: EXPERIMENTAL
Intervention: Massage intervention conducted by mothers for 2 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 112
Study: 29861804

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trigger Points (TrP) release by ischemic compression method
Number of subjects: 60
Study: 26962106

Group type: EXPERIMENTAL
Intervention: 6R-BH4 (sapropterin dihydrochloride)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23552390

Group type: EXPERIMENTAL
Intervention: Brief Mindfulness-Based Therapy (MBT), 6 sessions over 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 22490903

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg daily for 30 days
Number of subjects: 108

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily for 30 days
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg group
Number of subjects: 108
Study: 20354090

Group type: EXPERIMENTAL
Intervention: 0.05 percent cetylpyridinium chloride (CPC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.12 percent chlorhexidine (CHX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water
Number of subjects: 60

Group type: COMPARATOR
Intervention: No rinsing
Number of subjects: 60
Study: 17241506

Group type: EXPERIMENTAL
Intervention: Esmolol (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 45